Hemantane (N-2-adamantyl hexamethylenimine hydrochloride) - the novel antiparkinsonian drug in doses 10-20 mg/kg was shown to reduce tremor, rigidity and oligokinesis in animal models of parkinsonism. Hemantane was more effective than reference drug amantadine. In clinical study in patients with early stages of Parkinson’s disease hemantane reduced main parkinsonian symptoms in daily dose 25 mg. Nowadays clinical study of hemantane continues. Complex mechanism of action of hemantane was revealed. Hemantane is low affinity NMDA glutamate receptors ion channel inhibitor, similar to amantadine. Hemantane has properties of moderate reversible MAO B inhibitor, antioxidant activity, modulates dopaminergic and serotonergic receptors and monoamine transporters. The data obtained allows to suppose possible multi-targeting the pathogenesis of neurodegeneration. The purpose of the experimental studies of the last years was to evaluate neuroprotective potential of hemantane. 6-hydroxydopamine (6-OHDA)-induced injury in human neuroblastoma SH-SY5Y cell line and was used as an in vitro model of dopaminergic neurons for Parkinson’s disease research. Hemantane in concentrations 10-6 – 10-8 M prevents cytotoxic effect of 6-OHDA being administered in cell medium as before as well as after 6-OHDA. Preclinical (nonmotor) stage of Parkinson’s disease was modeled in rats by intranigral bilateral injections of neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (100 µg in 2 µl Ringer’s solution). Three weeks after surgery rats demonstrated cognitive deficit and depressive-like behavior without definite motor impairment. Pretreatment with hemantane (10 mg/kg) 5 days before MPTP and further administration during 3 weeks after MPTP preserve cognitive function and prevented depressive disturbances. To assess the inşuence of hemantane on the neuroinşammation model of Parkinson’s disease induced by lipopolysaccharide (LPS) was used. LPS (10 µg LPS in 2 µl Ringer’s solution) was injected into left substantia nigra pars compacta (SNc) according to stereotaxic coordinates. Hemantane (10 mg/kg) was administrated i.p. daily starting one day before the operation. Hemantane prevents induced by LPS weight loss, development of forepaw akinesia contralateral to the operation side and olfactory disturbance in rats. Anti-inşammatory effects of hemantane were confirmed in the models of peripheral inşammation – acetic acid peritonitis, carrageenan and concanavalin-A - induced paw edema. Effects of hemantane (10 mg/kg) and amantadine (20 mg/kg) were studied in the rat model of intracerebral posttraumatic hematoma. Drugs were administered first at 3,5 hours after surgery and then for 4 consecutive days. Effects were registered on days 1, 3, 7 and 14 after surgery. It was shown that both drugs significantly decreased mortality and improved motor activity, exploratory behavior and memory. Amantadine was more effective in tests for motor activity and exploratory behavior. Hemantane 5 mg/kg i.p. demonstrated more pronounced activity in restoring memory. All these data taken together allows concerning hemantane as antiparkinsonian drug with neuroprotective and neurorestorative potential with the ability for possible disease modifying activity.